Volume 68, Issue 5, Pages (November 2015)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 60, Issue 5, Pages (November 2011)

An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients.

Volume 63, Issue 3, Pages (March 2013)

Volume 70, Issue 5, Pages (November 2016)

Volume 66, Issue 2, Pages (August 2014)

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis Ian Cromwell, MSc, Kimberly.

European Urology Focus

Volume 70, Issue 6, Pages (December 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 70, Issue 6, Pages (December 2016)

Volume 60, Issue 2, Pages (August 2011)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

Volume 56, Issue 3, Pages (September 2009)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 69, Issue 1, Pages (January 2016)

Volume 74, Issue 2, Pages (August 2018)

Volume 51, Issue 5, Pages (May 2007)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 70, Issue 5, Pages (November 2016)

Volume 71, Issue 2, Pages (February 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 4, Pages (April 2013)

Volume 73, Issue 4, Pages e116-e118 (April 2018)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 66, Issue 2, Pages (August 2014)

Volume 65, Issue 3, Pages (March 2014)

Volume 71, Issue 3, Pages (March 2017)

Volume 70, Issue 4, Pages (October 2016)

Volume 70, Issue 5, Pages (November 2016)

Volume 64, Issue 5, Pages (November 2013)

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Prostate Cancer Epidemic in Sight?

Volume 53, Issue 2, Pages (February 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 70, Issue 2, Pages (August 2016)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Volume 50, Issue 5, Pages (November 2006)

Volume 73, Issue 4, Pages e116-e118 (April 2018)

Volume 70, Issue 6, Pages (December 2016)

Bernard Escudier European Urology Supplements

Volume 74, Issue 3, Pages (September 2018)

Volume 75, Issue 3, Pages (March 2019)

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based.

Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung.

Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

European Urology Oncology

Volume 76, Issue 1, Pages (July 2019)

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

European Urology Oncology

European Urology Oncology

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Presentation transcript:

Volume 68, Issue 5, Pages 837-847 (November 2015) SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer Christian Eichelberg, Walter L. Vervenne, Maria De Santis, Ludwig Fischer von Weikersthal, Peter J. Goebell, Christian Lerchenmüller, Uwe Zimmermann, Monique M.E.M. Bos, Werner Freier, Silke Schirrmacher-Memmel, Michael Staehler, Sascha Pahernik, Maartje Los, Marcus Schenck, Anne Flörcken, Cornelis van Arkel, Kirsten Hauswald, Martin Indorf, Dana Gottstein, Maurice S. Michel European Urology Volume 68, Issue 5, Pages 837-847 (November 2015) DOI: 10.1016/j.eururo.2015.04.017 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Patient disposition. a Reasons for stopping treatment as reported by the investigator. b Other reasons included investigator decision, lost to follow-up, and noncompliance. So=sorafenib; Su=sunitinib. European Urology 2015 68, 837-847DOI: (10.1016/j.eururo.2015.04.017) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Kaplan-Meier plots of (A) total progression-free survival and (B) overall survival (intention-to-treat population). CI=confidence interval; HR=hazard ratio; PFS=progression-free survival; OS=overall survival; So=sorafenib; Su=sunitinib. European Urology 2015 68, 837-847DOI: (10.1016/j.eururo.2015.04.017) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 Kaplan-Meier plots of (A) first-line progression-free survival and (B) second-line progression-free survival (intention-to-treat population). CI=confidence interval; HR=hazard ratio; PFS=progression-free survival; So=sorafenib; Su=sunitinib. European Urology 2015 68, 837-847DOI: (10.1016/j.eururo.2015.04.017) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 4 Forest plots of (A) total progression-free survival; (B) overall survival, and (C) first-line progression-free survival by subgroups (intention-to-treat population). a p values are for superiority of So-Su over Su-So. Significant differences for So-Su over Su-So or Su-So over Su-So are highlighted in bold. b In patients aged ≤65 yr, the p value for superiority of So-Su over Su-So was 0.98. When the superiority test is reversed, this gives a significant value of p=0.02 for superiority of Su-So over So-Su. In patients aged >65 yr, p=0.02 for superiority of So-Su over Su-So. CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; MSKCC=Memorial Sloan Kettering Cancer Center; So=sorafenib; Su=sunitinib. European Urology 2015 68, 837-847DOI: (10.1016/j.eururo.2015.04.017) Copyright © 2015 European Association of Urology Terms and Conditions